CNTA Centessa Pharmaceuticals plc
P/E
--
Forward P/E
-22.75281
Price/Sales
--
Beta
1.121
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Lee Ainslie's Maverick Capital exits Centessa Pharma following Lilly acquisition
Lee Ainslie's Maverick Capital fully exited its position in Centessa Pharmaceuticals (CNTA) during the second quarter of 2026, according to a recent SEC 13F...
Farallon exits Centessa Pharmaceuticals stake following Eli Lilly acquisition
Regulatory filings from mid-August show that Farallon Capital Management sold its entire stake in Centessa Pharmaceuticals during the second quarter. This...
Perceptive Advisors exits $209M Centessa stake following Eli Lilly acquisition
Perceptive Advisors, a major life sciences investor, exited its entire position in Centessa Pharmaceuticals during the second quarter of 2026, according to a...